This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Discussing the positive results from the Phase 2 Study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for HAE

Ticker(s): NTLA

Who's the expert?

Institution: Aloha Allergy

  • Allergist & Immunologist providing care for both pediatric and adult patients and has been practicing in allergy and immunology since 2010.
  • Currently manages 12 patients with Hereditary Angioedema.
  • Scientific interests include integrative approaches to allergies and asthma, exercise induced asthma, urticaria, and anaphylaxis with "novel" therapeutic modalities.

Interview Goal
.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.